Latest Asx News

Kalamazoo Resources Limited reported a $449,000 net cash outflow from operating activities in Q2 2024, maintaining a cautious stance as it explores funding options to sustain its exploration efforts.

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.

360 Capital Group has announced a fully franked dividend of AUD 0.02 per security for the six months ending December 31, 2024, payable on January 24, 2025. This update confirms the payment details and clarifies the distribution source.

Native Mineral Resources secures a conditional $6.5 million investment from entrepreneur Wes Maas, supporting its Queensland gold projects and targeting production restart in Q3 2025.

Phoslock Environmental Technologies reported a widening cashflow deficit and disappointing sales in the December 2024 quarter, while legal challenges and share suspension continue to cloud its outlook.

Patagonia Lithium has withdrawn its previously announced 15-year, 10,000 tonnes per annum production target, clarifying it was aspirational and not compliant with ASX Listing Rules. This retraction raises questions about the project's near-term viability and investor confidence.

Caspin Resources has completed its acquisition of the Bygoo Tin Project in NSW and is set to begin a significant drilling campaign, backed by a recent $1.6 million capital raise.

Kali Metals Limited has acknowledged a delay in lodging director interest notices due to an administrative oversight, reaffirming its commitment to ASX compliance and outlining existing disclosure procedures.

Ten Sixty Four Limited has received a crucial US$10.5 million payment from Philsaga Mining Corporation, enabling it to settle outstanding related party debts and advance its Deed of Company Arrangement.

Arafura Rare Earths Limited has acknowledged a breach of ASX Listing Rule 15.7 following premature media disclosure of a $200 million investment commitment from the National Reconstruction Fund Corporation. The company outlines corrective steps to prevent future compliance lapses.

Entyr Limited has launched a $9.5 million capital raising via a Share Purchase Plan and Placement Offer, aiming to recapitalize and return to ASX trading following its recent voluntary administration.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.